Patents Assigned to Entera Bio Ltd.
  • Publication number: 20220151919
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Applicant: Entera Bio Ltd.
    Inventors: Miriam KIDRON, Ehud ARBIT
  • Patent number: 11246827
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: February 15, 2022
    Assignee: Entera Bio Ltd.
    Inventors: Miriam Kidron, Ehud Arbit
  • Publication number: 20200138913
    Abstract: A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.
    Type: Application
    Filed: December 23, 2019
    Publication date: May 7, 2020
    Applicant: Entera Bio Ltd.
    Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
  • Patent number: 10583177
    Abstract: A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: March 10, 2020
    Assignee: Entera Bio Ltd.
    Inventors: Gregory Burshtein, Ariel Rothner, Phillip M. Schwartz, Hillel Galitzer
  • Publication number: 20190380953
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 19, 2019
    Applicant: Entera Bio Ltd.
    Inventors: Miriam KIDRON, Ehud ARBIT
  • Patent number: 10420721
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 24, 2019
    Assignee: Entera Bio Ltd.
    Inventors: Miriam Kidron, Ehud Arbit
  • Publication number: 20190209657
    Abstract: Pharmaceutical compositions comprising a therapeutically active agent and an absorption enhancer such as NAC, NAD, 5-CNAC, 4-MOAC, 4-CNAB or a salt thereof, for use in the treatment of a condition treatable by said therapeutically active agent, are provided. The compositions are for concomitant oral administration of two or more of the unit dosage form, which form together a therapeutically effective amount of the therapeutically active agent and an effective amount of the absorption enhancer. Multi-dose compositions comprising the two or more of the unit dosage form are also provided.
    Type: Application
    Filed: August 17, 2017
    Publication date: July 11, 2019
    Applicant: Entera Bio Ltd.
    Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
  • Publication number: 20180280292
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Applicant: Entera Bio Ltd.
    Inventors: Miriam KIDRON, Ehud ARBIT
  • Patent number: 10010503
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: July 3, 2018
    Assignee: Entera Bio Ltd.
    Inventors: Miriam Kidron, Ehud Arbit
  • Publication number: 20180036234
    Abstract: A pharmaceutical composition for use in the treatment of a medical condition associated with a bone fracture and/or a bone defect is provided herein, wherein the treatment is effected by oral administration of the composition. The composition comprises parathyroid hormone or a fragment thereof, and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate). Further disclosed are uses of the composition in the preparation of a medicament and methods of treating a bone fracture and/or bone defect utilizing the composition.
    Type: Application
    Filed: February 9, 2016
    Publication date: February 8, 2018
    Applicant: Entera Bio Ltd.
    Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
  • Publication number: 20180021272
    Abstract: A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.
    Type: Application
    Filed: February 9, 2016
    Publication date: January 25, 2018
    Applicant: Entera Bio Ltd.
    Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Philip M. SCHWARTZ, Hillel GALITZER
  • Publication number: 20160058699
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Application
    Filed: November 10, 2015
    Publication date: March 3, 2016
    Applicant: ENTERA BIO LTD.
    Inventors: Miriam KIDRON, Ehud ARBIT
  • Patent number: 9186412
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, methods for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: November 17, 2015
    Assignee: Entera Bio Ltd.
    Inventors: Miriam Kidron, Ehud Arbit